Jaguar Health shares slump following Phase III Mytesi failure

By Yahoo! Finance | Jul 23, 2024 at 12:23 PM EST

Jaguar Health's anti-diarrheal drug Mytesi did not meet its primary endpoint in a Phase III trial for cancer patients, causing shares to drop. The company plans to engage with the FDA for further analysis and explore other indications for the drug.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.